Psychedelic research company MindMed kicked off trading on Canadian stock exchange NEO this week, becoming one of the first of its kind to go public.
"We are the first publicly listed psychedelics company in the world. And I think what's really important about it is we take a clinical development approach through the FDA pathway. And this ultimately is the way forward for deploying and commercializing psychedelics," MindMed co-CEO and co-founder JR Rahn told Cheddar.
In advance of the reverse takeover transaction that took it public, MindMed raised $24.5 million from a variety of investors including Bail Capital, Cannell Capital, and Grey House, with participation from the founder of Toms Shoes Blake Mycoskie, and others. Shark Tank's Kevin O'Leary invested previously.
Almost 50 years after President Richard Nixon signed the Controlled Substances Act into law, psychedelic drugs are having a political and scientific renaissance in the U.S. Activists are pushing forward state-level and hyper-local decriminalization efforts. And research is well underway at top institutions all across the U.S., like at New York University and Johns Hopkins University, which received $17 million last year to launch a psychedelic research center. Promising research on drugs like psilocybin and LSD, which could be used for everything from fighting addiction to alleviating depression, has fueled interest and investment in the space. MindMed is one of many startups to take on the daunting task of bringing psychedelic-based drugs to market, focusing on 18-MC, which may allow for therapeutic uses without the hallucinogenic effect, for opioid addiction and microdosing LSD for adult ADHD.
"There's a lot of people going after psilocybin at the moment in terms of conducting clinical trials both in the academic realm, but also in the commercial realm and the nonprofit world. And we saw other forms of psychedelics that had such great therapeutic potential outcomes that it was thought a wiser way to go," Rahn said.
Ibogaine, a psychedelic drug derived from an African shrub, has shown promise as a treatment ー but a risky one ー for opioid addiction. 18-MC, a derivative of ibogaine, has fewer risks — plus, it's neither hallucinogenic nor scheduled under the Controlled Substances Act. It will likely be a long and expensive road before the Food and Drug Administration grants approval of a psychedelic-derived drug, but Rahn is hopeful the FDA may expedite trials on 18-MC since it shows promise for alleviating the opioid epidemic sweeping America.
The nature of the psychedelics space invites constant comparison to cannabis. But Rahn, like many others working in the field now, said the future of psychedelic drugs will be much different.
"What we are doing is federally legal and these are going to be medicines. We have no interest in recreational psychedelics," Rahn said. "This is a major message we are sending to the market. I don't think the cannabis folks really took this rigorous science and clinical trial approach."
Wealthfront’s CFO Alan Iberman talks the $2.05B IPO and the major moment for robo banking as the company bets on AI, automation, and “self-driving money."
A rare magnum of Dom Pérignon Vintage 1961 champagne that was specially produced for the 1981 wedding of Prince Charles and Lady Diana has failed to sell during an auction. Danish auction house Bruun Rasmussen handled the bidding Thursday. The auction's house website lists the bottle as not sold. It was expected to fetch up to around $93,000. It is one of 12 bottles made to celebrate the royal wedding. Little was revealed about the seller. The auction house says the bids did not receive the desired minimum price.
The New York Times and President Donald Trump are fighting again. The news outlet said Wednesday it won't be deterred by Trump's “false and inflammatory language” from writing about the 79-year-old president's health. The Times has done a handful of stories on that topic recently, including an opinion column that said Trump is “starting to give President Joe Biden vibes.” In a Truth Social post, Trump said it might be treasonous for outlets like the Times to do “FAKE” reports about his health and "we should do something about it.” The Republican president already has a pending lawsuit against the newspaper for its past reports on his finances.
OpenAI has appointed Slack CEO Denise Dresser as its first chief of revenue. Dresser will oversee global revenue strategy and help businesses integrate AI into daily operations. OpenAI CEO Sam Altman recently emphasized improving ChatGPT, which now has over 800 million weekly users. Despite its success, OpenAI faces competition from companies like Google and concerns about profitability. The company earns money from premium ChatGPT subscriptions but hasn't ventured into advertising. Altman had recently announced delays in developing new products like AI agents and a personal assistant.
President Donald Trump says he will allow Nvidia to sell its H200 computer chip used in the development of artificial intelligence to “approved customers” in China. Trump said Monday on his social media site that he had informed China’s leader Xi Jinping and “President Xi responded positively!” There had been concerns about allowing advanced computer chips into China as it could help them to compete against the U.S. in building out AI capabilities. But there has also been a desire to develop the AI ecosystem with American companies such as chipmaker Nvidia.
